Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tax inversion

- PMLiVE

Pfizer names next CEO as Read retires

Company's board elects current chief operating officer Dr Albert Bourla

- PMLiVE

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

- PMLiVE

FDA rejects Allergan’s uterine fibroid drug over safety concerns

Its investigational drug has been linked to 'serious' liver damage issues in Europe

- PMLiVE

Pfizer signs mRNA flu vaccine deal with BioNTech

Pharma giant will take on development and commercial responsibility for candidates

- PMLiVE

Industry appointments

Vivaldi heads up Sigilon, Pfizer Oncology loses its CMO and Zelluna appoints new CSO

- PMLiVE

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

- PMLiVE

Almirall acquires Allergan’s dermatology portfolio for $650m

The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links